Use of anti-infliximab antibody levels to monitor infliximab treatment in patients with inflammatory bowel disease (IBD)

Record ID 32013000587
Authors' recommendations: Crohn's disease (CD) and ulcerative colitis (UC) are progressive, inflammatory disorders of the gastrointestinal tract characterized by strictures, fistulae, abdominal pain, abnormal bowel function, and rectal bleeding. CD is usually diagnosed in young adulthood, and the incidence and prevalence of the disease have increased slightly in recent decades. In the adult population of the United States, the prevalence of CD is 241 per 100,000 individuals and the prevalence of UC is 263 per 100,000 individuals. UC tends to be more severe in younger patients, particularly children. Both disorders are associated with development of colorectal cancer. The major goal of treatment for IBD is mucosal healing using medical therapy. In the 9% to 35% of patients with UC in whom medical therapy fails, the treatment is colectomy.
Project Status: Completed
Year Published: 2013
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: United States
MeSH Terms
  • Inflammatory Bowel Diseases
  • Antibodies, Monoclonal
Organisation Name: HAYES, Inc.
Contact Address: 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
Contact Email:
Copyright: 2013 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.